Clinical Trial

MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC

Study acronym: Seagull
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 17, 2023 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Seagull is a phase Ⅱ study designed to investigate the efficacy and safety of MRD-guided adjuvant tislelizumab and chemotherapy vs adjuvant tislelizumab and chemotherapy in patients with resectable NSCLC
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-03-09.
Status change: Not Yet Recruiting → Recruiting 2023-03-15
Trial Details
NCT Number NCT05286957
Lead Sponsor The First Affiliated Hospital of Zhengzhou University
Collaborators: BeiGene
Conditions NSCLC
Enrollment 60 participants
Start Date 2022-06-20
Primary Completion 2026-06-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2023-03-17